Efpegerglucagon Biosimilar – Anti-GLP-1(7-36) mAb – Research Grade from ProteoGenix; catalogue PX-TA2156; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Efpegerglucagon Biosimilar – Anti-GLP-1(7-36) mAb – Research Grade is a novel therapeutic antibody that targets the glucagon-like peptide 1 (GLP-1) receptor. This biosimilar is designed to mimic the activity of the endogenous GLP-1 hormone, which plays a crucial role in regulating glucose homeostasis and satiety. In this article, we will discuss the structure, activity, and potential applications of this promising biosimilar.
Efpegerglucagon Biosimilar is a monoclonal antibody (mAb) that specifically binds to the GLP-1 receptor. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the GLP-1 receptor, while the constant regions provide stability and effector functions.
The structure of Efpegerglucagon Biosimilar is highly similar to the endogenous GLP-1 hormone, allowing it to bind to the GLP-1 receptor with high affinity. This structural similarity also minimizes the risk of immunogenicity, making it a safe and effective therapeutic option.
Once bound to the GLP-1 receptor, Efpegerglucagon Biosimilar activates downstream signaling pathways that regulate glucose metabolism and appetite. This includes the activation of adenylyl cyclase and subsequent production of cyclic adenosine monophosphate (cAMP), which leads to insulin secretion and inhibition of glucagon release from pancreatic cells. This results in improved glycemic control and reduced hyperglycemia in patients with diabetes.
In addition, Efpegerglucagon Biosimilar also exerts anorexigenic effects by stimulating the release of satiety hormones such as peptide YY (PYY) and glucagon-like peptide 2 (GLP-2). This can help in reducing food intake and promoting weight loss in obese individuals.
Efpegerglucagon Biosimilar has shown promising results in preclinical and clinical studies for the treatment of type 2 diabetes and obesity. In patients with type 2 diabetes, it has been shown to improve glycemic control, reduce body weight, and lower the risk of cardiovascular events. It has also been found to be well-tolerated and safe, with no significant adverse effects reported.
Moreover, Efpegerglucagon Biosimilar has the potential to be used in combination with other antidiabetic agents, such as insulin and oral hypoglycemic drugs, to achieve better glycemic control and reduce the risk of hypoglycemia. It may also be beneficial for patients with obesity and metabolic syndrome, as it can promote weight loss and improve metabolic parameters.
Efpegerglucagon Biosimilar – Anti-GLP-1(7-36) mAb – Research Grade is a promising therapeutic antibody that targets the GLP-1 receptor. Its structure and activity closely resemble the endogenous GLP-1 hormone, making it a safe and effective treatment option for type 2 diabetes and obesity. Further research and clinical trials are needed to fully evaluate its potential and expand its therapeutic applications.
ProteoGenix catalogue number PX-TA2156. For research use only.
Target: Efpegerglucagon Biosimilar – Anti-GLP-1(7-36) mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Efpegerglucagon Biosimilar – Anti-GLP-1(7-36) mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
